Oral and Skin Pigmentations associated with hydroxyurea therapeutic doses in a patient with sickle cell disease: Case Report

Authors

  • Aesa Alzaroug Jaber Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Sebha University, Libya.
  • Almahdi. A. Jaber Department of Pathology and Clinical Pathology, Faculty of Veterinary Medicine, Tripoli University, Libya.
  • Alshame M.J. Alshame Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Sebha University, Libya.

DOI:

https://doi.org/10.51984/joms.v18i1.2606

Keywords:

Sickle cell Disease, Hydroxyurea, Hyperpigmentation, Oral Cavity

Abstract

Hydroxyurea is an effective treatment for Sickle cell disease. Hydroxyurea has classified as an antineoplastic agent and is also prescribed as Antisickling agent; it works through inhibition of DNA synthesis at S phase. Despite Hydroxyurea benefits sickle cell patients, undesirable side effect such as leukopenia and hyperpigmentation were observed. Hydroxyurea-induced hyperpigmentation is mainly seen in the skin and rarely in the oral cavity. Although Hydroxyrea-induced pigmentation is benign and reversible, this mild pathological condition should have considered.

Downloads

Download data is not yet available.

Author Biographies

  • Aesa Alzaroug Jaber, Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Sebha University, Libya.

    Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Sebha University, Libya.

  • Almahdi. A. Jaber, Department of Pathology and Clinical Pathology, Faculty of Veterinary Medicine, Tripoli University, Libya.

    Department of Pathology and Clinical Pathology, Faculty of Veterinary Medicine, Tripoli University, Libya.

  • Alshame M.J. Alshame, Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Sebha University, Libya.

    Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Sebha University, Libya.

Downloads

Published

2023-06-05

How to Cite

Oral and Skin Pigmentations associated with hydroxyurea therapeutic doses in a patient with sickle cell disease: Case Report. (2023). Journal of Medical Sciences, 18(1), 31-34. https://doi.org/10.51984/joms.v18i1.2606

Similar Articles

1-10 of 48

You may also start an advanced similarity search for this article.